Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-01

Study Completion Date

2025-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study postulates that altered microbiota associated with areas of mucosal inflammation in CD, can be characterized by an increased proteolytic profile. This is clinically important as it may be possible to modulate the proteolytic activity of the CD-associated bacteria by using other bacteria that produce protease inhibitors, such as serpins.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting IBD Treatment Outcomes With Gut Microbiome Analysis

NCT06453720

Inflammatory Bowel Diseases Crohn Disease

RECRUITING

Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD

NCT07169123

Crohns Disease

NOT_YET_RECRUITING

Microbial Community Characteristics in Intestinal Mucosal Tissue of Patients With CD

NCT06895772

Crohn's Disease (CD)

ACTIVE_NOT_RECRUITING

The Microbial Impact on Intestinal Fibrosis and the Associated Immune Microenvironment in Crohn's Disease

NCT06720961

Crohn Disease (CD)

NOT_YET_RECRUITING

The Gut Virome as a Trigger for IBD: From Metagenomics to Pathogenesis

NCT05906680

IBD

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Crohn's disease (CD), characterized by discontinuous intestinal injury and inflammation, has been associated with changes in the luminal microbiota and impaired barrier function. Previously, the investigators have shown that in patients with CD, the mucosa-associated microbiota is altered. Additionally, it has been shown that in patients with active CD, areas of intestinal injury are associated with impaired barrier function, but the mechanisms remain unclear. Increased host proteolytic activity has been reported in both CD and ulcerative colitis (UC). The microbiota is an important source of proteases with potential inflammatory and barrier disrupting capacity. Indeed, preliminary data indicate that in UC patients the gut microbiota contributes to proteolytic imbalance. It is unknown whether this is also the case in CD. Specifically, this study postulates that the altered microbiota associated with areas of mucosal inflammation in CD, is characterized by an increased proteolytic profile. This is clinically important as it may be possible to modulate the proteolytic activity of the CD-associated bacteria by using other bacteria that produce protease inhibitors such as serpins.

In this prospective observational study, patients booked for routine white light colonoscopy under the care of the Division of Gastroenterology, Hamilton Health Sciences at the McMaster University Medical Centre and Juravinski Hospital Endoscopy Units will be invited to participate. Patients previously diagnosed with Crohn's disease who have a clinical indication for undergoing a standard white light colonoscopy, as determined by the gastroenterologist, will be invited to participate; biopsy samples and mucosal brushings will be taken from inflamed and non-inflamed areas in the ileum or colon.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease of Both Small and Large Intestine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients previously diagnosed with Crohn's disease who have a clinical indication for undergoing a standard white light colonoscopy, as determined by their gastroenterologist, will be invited to participate. Patients undergoing colonoscopy for other indications (for example, for the investigation of possible malignancy, polyps, gastrointestinal bleeding or diarrhea, without colonic inflammation), will not be included in this study.

Colonoscopy

Intervention Type PROCEDURE

Colonoscopy with video recording and biopsy collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colonoscopy

Colonoscopy with video recording and biopsy collection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be aged between 18 - 70 years old
* Have a confirmed diagnosis of Crohn's disease
* Have a clinical indication for standard, white light colonoscopy to assess disease activity and extent

Exclusion Criteria

* Inability to provide written informed consent
* Presence of serious life-threatening co-morbidities
* Evidence of toxic megacolon, jaundice, cirrhosis, renal dysfunction, acute GI bleeding
* History of difficult colonoscopy, strictures or extensive diverticulosis
* Antibiotics in the last month
* Probiotics in the last week

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No